Kagocel-B (01167) announced that the company will present at the 66th annual American Society of Hematology (ASH) in 2024...
Smart Finance APP news, Kagocel-B (01167) announced that the company will showcase the clinical data of the BET inhibitor JAB-8263 at the 66th annual American Society of Hematology (ASH) in 2024. The ASH conference will be held in San Diego, USA from December 7th to 10th, 2024, and more conference information will be announced after November 5th, 2024, Eastern Time.
Kagocel is committed to providing breakthrough treatment solutions for patients. The company's research projects focus on six major tumor signaling pathways: KRAS, tumor immunity, tumor metabolism, P53, RB, and MYC, with the goal of being among the top three globally. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. Kagocel's laboratories are located in Peking, shanghai, and Boston, with the Inducing Allosteric Drug Discovery Platform (IADDP) and Immuno-stimulatory Antibody Conjugation Drug (iADC) development platforms.
